GlassScriptPhysician profile
Habib Monas
NPI 1568554616
$2,590.62
in general payments reported to CMS, 2019-2025
20 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $766 · 2020: $717 · 2021: $319 · 2022: $380 · 2023: $104 · 2024: $203 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $825.02 | 2019-2025 | Airsupra |
| Novo Nordisk INC | $252.41 | 2020-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $230.58 | 2019-2020 | |
| Glaxosmithkline, LLC. | $203.23 | 2020-2021 | |
| Abbvie INC. | $197.50 | 2021-2024 | |
| Althera Pharmaceuticals LLC | $153.00 | 2022 | |
| Abbott Laboratories | $129.01 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $112.59 | 2019 | |
| Intuity Medical INC | $111.12 | 2022 | |
| Amgen INC. | $73.14 | 2023-2025 | Otezla, Repatha, Repatha |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $60.34 | 2021 | |
| Amarin Pharma, INC. | $56.82 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.08 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $30.37 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $25.86 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $25.71 | 2024 | Rexulti |
| Phathom Pharmaceuticals, INC. | $18.29 | 2025 | Voquezna |
| International Rehabilitative Sciences, INC | $14.51 | 2024 | Rs 4i Plus Sequential Stimulator |
| Lilly USA, LLC | $13.79 | 2021 | |
| Shionogi INC | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Habib Monas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.